Why Target the Gut to Treat IgA Nephropathy?
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu úvodníky
PubMed
33102954
PubMed Central
PMC7569689
DOI
10.1016/j.ekir.2020.08.009
PII: S2468-0249(20)31447-9
Knihovny.cz E-zdroje
Division of Nephrology Ohio State University Wexner Medical Center Columbus Ohio USA
General University Hospital 1st Faculty of Medicine Charles University Prague Czech Republic
Stanford Glomerular Disease Center Stanford University Medical Center Stanford California USA
Toronto General Hospital Research Institute Toronto Ontario Canada
University Hospital Rheinisch Westfälische Technische Hochschule Aachen Germany
Zobrazit více v PubMed
Berger J., Hinglais N. [Intercapillary deposits of IgA-IgG] J Urol Nephrol (Paris) 1968;74:694–695. PubMed
Wyatt R.J., Julian B.A. IgA nephropathy. N Engl J Med. 2013;368:2402–2414. PubMed
Thompson A., Carroll K., L A.I. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14:469–481. PubMed PMC
Kidney Disease Improving Global Outcomes Glomerulonephritis Work Group KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.
Lafayette R.A., Canetta P.A., Rovin B.H. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–1313. PubMed PMC
Lv J., Zhang H., Wong M.G. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318:432–442. PubMed PMC
Rauen T., Eitner F., Fitzner C. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–2236. PubMed
Selvaskandan H., Cheung C.K., Muto M. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019;23:577–588. PubMed PMC
The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies
